Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

CompletedOBSERVATIONAL

Enrollment

4,320

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Ribociclib

Participants who initiated CDK4/6i therapy

DRUG

Palbociclib

Participants who initiated CDK4/6i therapy

DRUG

Abemaciclib

Participants who initiated CDK4/6i therapy

Trial Locations (1)

Novartis Investigative Site, East Hanover